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was estimated by time-adjusted Cox proportional hazards
regression.
RESULTS Among 8,582 “all-comers” patients who underwent suc-
cessful PCI with DES in the ADAPT-DES study, PDB occurred in 535/
8,577 hospital survivors (6.2%) at a median time of 300 days (inter-
quartile range: 130 to 509 days) after hospital discharge. Gastroin-
testinal bleeding (61.7%) was the most frequent source of PDB.
Predictors of PDB included older age, lower baseline hemoglobin,
lower platelet reactivity on clopidogrel, and use of chronic oral anti-
coagulation therapy. PDB was associated with higher crude rates of
all-cause mortality (13.0% vs. 3.2%; p<0.0001; Figure). Following
multivariable adjustment, PDB was strongly associated with 2-year
mortality (HR: 5.03; 95% CI: 3.29–7.66; p<0.0001), with an effect
size greater than that of post-discharge myocardial infarction (PDMI)
(HR: 1.92; 95% CI: 1.18–3.12; p¼0.009).
CONCLUSIONS Following successful PCI with DES in an unrestricted
patient population, PDB is not uncommon, and has a strong rela-
tionship with subsequent all-cause mortality, greater that that asso-
ciated with PDMI. Efforts to reduce PDB may further improve
prognosis after successful DES implantation.
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BACKGROUND The PE Plus Post-Approval Study (PE Plus PAS) was
designed to examine long-term outcomes among patients treated
with advanced generation, everolimus-eluting, platinum chromium
PROMUS Element stents (Boston Scientiﬁc, Marlborough, MA) in
unselected patients treated in routine practice. This is the ﬁrst
report of 2-year results from this large multicenter post-approval
study.
METHODS PE Plus PAS was a prospective, open-label, multicenter
observational study enrolling 2684 patients at 52 sites in the US.
Follow-up was at 30 days, 6 months, and 1 year, and will continue
annually through 5 years. The primary endpoint was 12-monthcardiac death or myocardial infarction (CD/MI) in ‘PLATINUM-like’
patients who received PROMUS Element Plus in PE Plus PAS, PE
PROVE and patients from the PLATINUM Workhorse/Small Vessel
trials compared to a performance goal (3.2%) derived from out-
comes in SPIRIT IV and the PLATINUM trial. The PLATINUM-like
patient cohort was deﬁned as all patients that met the criteria for
enrollment in the PLATINUM trial. A Clinical Events Committee
adjudicated major adverse cardiac events and their relatedness to
the study stent.
RESULTS In the PE Plus PAS, 30% of patients were female, mean
age was 64 years, 37% had medically treated diabetes, and more
than three-quarters were treated for hyperlipidemia and hyperten-
sion. At baseline, mean lesion length was 1710 mm and mean
reference vessel diameter was 2.90.5 mm (in 3595 treated lesions).
PLATINUM-like patients accounted for 29% of the overall PE Plus
PAS patient population. For the primary endpoint, 12-month CD/MI
in PLATINUM-like patients was 1.8% (33/1855) with a upper 1-sided
95% conﬁdence interval of 2.3%, which was signiﬁcantly less than
the prespeciﬁed performance goal of 3.2% (Pnoninferiority<0.001).
In the overall PE Plus population, 12-month major adverse cardiac
events were low.
CONCLUSIONS The 2-year results from the PE Plus PAS will be
available for presentation for the ﬁrst time at TCT 2015 and will show
favorable performance and safety for the PROMUS Element Plus
everolimus-eluting stent at 2 years in an unselected patient
population.
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BACKGROUND The beneﬁt on prognosis after successful recanaliza-
tion of chronic total occlusion (CTO) lesions is uncertain.
METHODS A total of 1173 consecutive patients (mean age 60 years,
82.7% men) with CTOs of native coronary vessels in which per-
cutaneous coronary intervention (PCI) was attempted was enrolled
from March 2003 and May 2014. All successful procedures
(1004 patients, 85.6%) were performed by drug-eluting stent
implantation.
RESULTS During a median of 4.6-year of follow-up, the cumulative
incidence of all-cause death was not signiﬁcantly different between
the successful and unsuccessful CTO-PCI (8.0% vs. 7.1%, P ¼ 0.83).
The cumulative rate of target vessel revascularization (TVR) and
coronary artery bypass grafting (CABG) was remarkably less in
patients with successful PCI compared with those with unsuc-
cessful PCI (TVR; 4.4% vs. 20.9%, P < 0.001, CABG; 0.4% vs.
16.7%, P < 0.001). The adjusted risks of all-cause death (hazard
ratio [HR] 1.19, 95% conﬁdence interval [CI] 0.59 – 2.43, P ¼ 0.62)
and the composite of death or myocardial infarction ([MI], HR 1.06,
95% CI 0.56 – 2.03, P ¼ 0.96) remained comparable between
groups, whereas the adjusted risk of TVR and CABG was signiﬁ-
cantly higher in patients with unsuccessful CTO PCI. Among 879
subjects who eventually had a complete revascularization state for
the non-CTO vessels, the risks of death or the composite of death
or MI were not different between patients who further underwent
successful recanalization of the remaining CTO and those who
did not. This ﬁnding was consistent regardless of whether the
patient had a multi-vessel disease including CTO or only had a
single CTO.
CONCLUSIONS Successful CTO-PCI compared with unsuccessful PCI
was not associated with lesser risk for 4.6-year mortality, but was
associated with signiﬁcantly less subsequent CABG.
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BACKGROUND EndoVascular Aneurysm Repair (EVAR) is a new treat-
ment option for patients with abdominal aortic aneurysm (AAA) with
suitable anatomy. The objective was to compare outcomes of EVAR and
open surgery for the elective and emergent management of AAA.
METHODS We conducted a systematic search of the Pub Med and
Cochrane databases for randomized clinical trials (RCTs) comparing
the outcomes of EVAR and opened surgery for the elective and
emergent management of AAA repair. We also combined the overall
results of these two sub-analysis. The primary endpoint was mortality
at 30 days post-procedure. The data were analyzed using the inten-
tion-to-treat principle. In addition, we applied random or ﬁxed effect
analysis according to the Cochrane-Handbook of Systematic Reviews
and RevMan 5.2 for statistical analysis.
RESULTS The search produced 254 studies, of which only 7 were
RCTs. 4 RCTS for AAA elective repair included 2031 patients (1089
EVAR; 942 surgery); and 3 studies on ruptured aneurysm included a
total of 761 patients (388 EVAR; 373 surgical). There was signiﬁcant
less mortality in the EVAR group of patients treated for elective AAA
in comparison to patients treated with surgery (1.4% vs. 3.5%;
p¼0.009). Among patients treated for ruptured aneurysm, there was
no mortality difference (34 % vs. 36%; p¼0.5). Overall analysisdemonstrated a trend toward lower mortality rates in patients treated
with EVAR (10% vs. 12.7%, p¼0.07) (Figure 1).
CONCLUSIONS Our analysis suggests that the use of EVAR for pa-
tients with AAA can lead to good outcomes not only for elective repair
but also for ruptured aneurysm. It is yet to be determined if these
beneﬁts are sustained in time. Therefore RCTs with longer follow-up
are warranted.
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BACKGROUND Stroke is the third leading cause of death and the most
common cause of disability in the United States. Early reperfusion has
been associated with favorable outcomes. Stent retrievers are novel
endovascular devices which provide vessel recanalization via
thrombus retrieval mechanical thrombectomy.
METHODS We performed a literature search using PubMed,
EMBASE, and Cochrane Central Register of Controlled Trials from
May 2005 to May 2015. Randomized controlled trails (RCTs)
comparing endovascular therapy (ET) with the use of retrievable
stents against standard therapy (ST) for the management of acute
stroke were included.
RESULTS Five RCTs (MR CLEAN, ESCAPE, EXTEND-IA, SWIFT-
PRIME and REVASCAT) with 634 patients in ET group and 653 pa-
tients in ST group met inclusion criteria. The frequency of a low 90-
day modiﬁed Rankin score (0-2) in the intervention group was
42.6% compared with 26.1% in the control group (OR 2.43 (1.9,
3.09); P<0.0001). The frequency of intracranial bleeding was 4.2%
in the ET group compared with 4.4% in the ST group (RR 1.06 (0.63,
1.78); P¼0.84) 90-day mortality was 15.1% in the ET group
compared with 18.7% in the ST group (RR 0.81 (0.58, 1.12; P¼0.19).
There was no evidence of signiﬁcant heterogeneity or publication
bias for any of the endpoints.
